Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for purine and pyrimidine synthesis. This halts DNA, RNA, and protein production in rapidly dividing cells and also increases adenosine release, which reduces inflammation and suppresses immune activity.

The dose of Methofill is individualized. A qualified prescriber determines the appropriate amount, frequency, and duration based on the specific indication, patient characteristics, and clinical response. No standard dosing regimen is provided here.

Methofill is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as methotrexate can be excreted in breast milk and affect the infant.

To order Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Methofill (methotrexate) is a conventional synthetic DMARD that is less expensive and orally or subcutaneously administered, unlike many biologics that require intravenous infusion. While biologics target specific cytokines, methotrexate has a broader anti‑inflammatory effect and is often used as first‑line therapy before escalating to biologic agents.

Methofill should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to local regulations.

Methofill is supplied as a sterile solution for subcutaneous injection. The injection is typically given into the abdomen or thigh using a suitable needle, following aseptic technique. Patients or healthcare professionals should rotate injection sites to reduce local irritation.

The most serious risks include bone marrow suppression leading to pancytopenia, severe hepatotoxicity or liver fibrosis, and pulmonary toxicity such as interstitial pneumonitis. These adverse events require regular laboratory monitoring and immediate medical attention if symptoms arise.

Methofill should not be used by pregnant or breastfeeding women, patients with severe renal impairment, those with pre‑existing liver disease, or individuals with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with active infections.